HOME
PRODUCTS
COMPANY
CONTACT
FAQ
Research
Dictionary
Pharma
Sign Up
FREE
or
Login
Username:
Password:
Remember login
Login
Send password reminder...
daltroban
thromboxane antagonist
Also Known As:
4-(2-(4-chlorobenzenesulfonylamino)ethyl)benzeneacetic acid; 4-(2-(4-chlorophenylsulfonylamino)ethyl)phenylacetic acid; BM 13.505; BM 13505; BM-13505; SKF 96148; SKF-96148
Networked:
31
relevant articles (
4
outcomes,
7
trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Organic Chemicals: 133
Amides: 2428
Sulfonamides: 2809
daltroban: 31
Carboxylic Acids: 973
Carbocyclic Acids
Phenylacetates: 3
daltroban: 31
Sulfur Compounds: 278
Sulfones: 534
Sulfonamides: 2809
daltroban: 31
Experts
1.
Kylhammar, D
: 1 article (08/2012)
2.
Rådegran, G
: 1 article (08/2012)
3.
Auchampach, John A
: 1 article (03/2003)
4.
Ge, Zhi-Dong
: 1 article (03/2003)
5.
Gross, Garrett J
: 1 article (03/2003)
6.
Piper, Galen M
: 1 article (03/2003)
Related Diseases
1.
Atherosclerosis
01/01/1992 - "
In rabbits fed CH-enriched diet treatment with daltroban led to an inhibition of platelet aggregation and to a significant reduction of progression of atherosclerosis.
"
01/01/1992 - "
Both reduced CH esterification and TXA2 receptor antagonism may contribute to the diminution of progression of atherosclerosis by daltroban.
"
01/01/1991 - "
Atherosclerosis in the aorta of hypercholesterolemic rabbits and the influence of daltroban.
"
01/01/1991 - "
These studies have examined aortic atherogenesis in cholesterol-fed rabbits and have correlated the effects of daltroban to the pathomechanism of the vessel wall lesions.
"
01/01/1992 - "
Effects of daltroban, a thromboxane (TX) A2 receptor antagonist, on lipid metabolism and atherosclerosis.
"
2.
Reperfusion Injury
12/01/1990 - "
Thus, daltroban significantly protected the myocardium from reperfusion injury without protecting the coronary endothelium or retarding neutrophil accumulation.
"
10/01/1989 - "
In MI/R-BM 13.505 treated animals, reperfusion injury was reduced by 50% to 19 +/- 7% of the left ventricle (p less than 0.05, compared to the MI/R-vehicle group).
"
12/01/1990 - "
Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
"
04/01/1989 - "
Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
"
04/01/1989 - "
The ability of BM-13505, 4-[2-(4-chlorobenzenesulfonylamino) ethyl]-benzene acetic acid), a specific thromboxane/endoperoxide receptor antagonist, to protect the myocardium against ischemia and reperfusion injury, was assessed in an anesthetized cat model.
"
3.
Myocardial Ischemia (Ischemic Heart Diseases)
12/01/1990 - "
The effects of daltroban, a specific thromboxane receptor antagonist, were investigated in a model of myocardial ischemia consisting of 1.5 h of coronary artery occlusion followed by reperfusion for 4.5 h in anesthetized cats.
"
12/01/1990 - "
Daltroban, a thromboxane receptor antagonist, protects the myocardium against reperfusion injury following myocardial ischemia without protecting the coronary endothelium.
"
04/01/1989 - "
Protective effect of the specific thromboxane receptor antagonist, BM-13505, in reperfusion injury following acute myocardial ischemia in cats.
"
03/01/2003 - "
The purpose of the current study was to compare the efficacy of two structurally unrelated thromboxane A (TXA ) receptor antagonists, KT2-962 and daltroban (BM 13.505), in a dog model of myocardial ischemia/reperfusion injury.
"
4.
Sudden Death
01/01/1988 - "
The injection of U 46619 (100 micrograms/kg i.v.) produced sudden death typically between 5 and 15 min. Administration of 0.01 mg/kg BM 13.505 (i.v.) 0.1 h prior to the U 46619 challenge did not protect against sudden death, while doses of 0.03 mg/kg or greater protected completely (100% survival).
"
01/01/1988 - "
Administration of a single dose of BM 13.505 5 min or 24 h prior to the challenge with U 46619 protected completely against sudden death (100% survival, p less than 0.01), while injection of BM 13.505 48 h prior to the U 46619 challenge did not protect against death.
"
01/01/1988 - "
Protective effects of the thromboxane receptor antagonists BM 13.177 and BM 13.505 against U 46619-induced sudden death in rats.
"
01/01/1988 - "
The purpose of this study was to evaluate the pharmacology and pharmacodynamics of the thromboxane receptor antagonists, BM 13.177 and BM 13.505, for prevention of U 46619-induced sudden death in anesthetized male Sprague-Dawley rats.
"
01/01/1988 - "
These data demonstrate that BM 13.177 and BM 13.505 prevented sudden death produced by the injection of U 46619.
"
5.
Hyperplasia
01/01/1991 - "
There was no inhibition of intimal hyperplasia (P greater than 0.05) after either iloprost (I/M ratio: 1.04 +/- 0.13; N = 8) or daltroban (I/M ratio: 0.70 +/- 0.04; N = 6).
"
01/01/1991 - "
It is concluded that neither of these two modulators of eicosanoid activity, iloprost and daltroban, inhibit intimal hyperplasia following experimental endothelial injury.
"
01/01/1991 - "
This study evaluated the efficacy of a prostacyclin analog, iloprost, and a thromboxane A2 receptor antagonist, daltroban, as inhibitors of experimental intimal hyperplasia.
"
01/01/1991 - "
Evaluation of a prostacyclin analog, iloprost, and a thromboxane A2 receptor antagonist, daltroban, in experimental intimal hyperplasia.
"
Related Drugs and Biologics
1.
daltroban
2.
Thromboxane Receptors (Thromboxane Receptor)
3.
Thromboxanes
4.
Prostaglandin H2 Thromboxane A2 Receptors
5.
sulotroban
6.
Iloprost (Ventavis)
7.
Epoprostenol (Prostacyclin)
8.
6- isopropyl- 3- (4- (4- chlorobenzenesulfonylamino)butyl)azulene- 1- sulfonic acid sodium salt
9.
Thromboxane-A Synthase
10.
Cholesterol